• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    7/14/23 12:53:59 PM ET
    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Electrical Products
    Industrials
    Get the next $ACAD alert in real time by email

    Gainers

    • PainReform Ltd. (NASDAQ:PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement.
    • EdtechX Holdings Acquisition Corp. II (NASDAQ:EDTX) shares climbed 46.3% to $63.24 after jumping 203% on Thursday.
    • Frequency Therapeutics, Inc. (NASDAQ:FREQ) gained 41.7% to $0.5669 after the company agreed to merge with Korro Bio in an all- stock transaction.
    • Ainos, Inc. (NASDAQ:AIMD) surged 38% to $1.0082.
    • Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) gained 33.4% to $6.15.
    • Envirotech Vehicles, Inc. (NASDAQ:EVTV) climbed 29.2% to $3.10.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) rose 25% to $1.0699.
    • Chijet Motor Company, Inc. (NASDAQ:CJET) climbed 21.1% to $3.7738. Chijet Motor Company's majority-owned subsidiary achieved a breakthrough in export model.
    • Canoo Inc. (NASDAQ:GOEV) gained 21.1% to $0.6728.
    • Western Acquisition Ventures Corp. (NASDAQ:WAVS) gained 18.2% to $12.28.
    • ARB IOT Group Limited (NASDAQ:ARBB) shares rose 18% to $3.84 after gaining around 12% on Thursday.
    • TMC the metals company Inc. (NASDAQ:TMC) climbed 16.7% to $2.1250.
    • ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) gained 15.6% to $29.83. Acadia Pharmaceuticals acquired ex-North American rights to trofinetide and global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.
    • Aehr Test Systems (NASDAQ:AEHR) gained 14.4% to $47.80 as the company reported better-than-expected results for its fourth quarter. The company said it sees FY24 revenue to be at least $100 million and GAAP net income of at least $28 million.
    • 1847 Holdings LLC (NYSE:EFSH) rose 14% to $0.2850. 1847 projects revenue of $20 million for the second quarter.
    • Nutriband Inc. (NASDAQ:NTRB) gained 13.6% to $2.7299. Nutriband increased existing credit line to $5 million supporting the continued development of its AVERSA platform towards FDA submission.
    • Nikola Corporation (NASDAQ:NKLA) shares rose 13.1% to $2.5115 after gaining over 60% on Thursday. The company and BayoTech announced an agreement to advance reliable hydrogen supply for zero-emission commercial fuel cell electric vehicle fleets.
    • Ambow Education Holding Ltd. (NYSE:AMBO) gained 13% to $0.2293.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) rose 12% to $34.52. Cantor Fitzgerald reiterated Arcturus Therapeutics with an Overweight and maintained a $54 price target.
    • Elanco Animal Health Incorporated (NYSE:ELAN) gained 10.4% to $11.70 after the company announced the EPA completed its review of the Seresto collar and confirmed continued registration of the collar.
    • Shengfeng Development Limited (NASDAQ:SFWL) climbed 10.2% to $6.35.
    • Intuitive Machines, Inc. (NASDAQ:LUNR) shares rose 9.5% to $9.35. Intuitive Machines is closing in on delivering its Nova-C lunar lander to Florida for launch. The company said on Thursday that it has successfully conducted a complete spacecraft test run of the lander.
    • GT Biopharma, Inc. (NASDAQ:GTBP) shares gained 8.1% to $0.3039.
    • Ainos, Inc. (NASDAQ:AIMD) gained 37% to $1.0001 after gaining around 7% on Thursday.

    Losers

    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) shares dipped 69.9% to $2.87 after the company announced discontinuing enrollment in Phase 1/2 study and terminating development of THE-630 for gastrointestinal stromal tumors following two dose-limiting toxicities.
    • Canopy Growth Corporation (NASDAQ:CGC) fell 37% to $0.4088. Cannabis company announced it has entered into a series of agreements, including privately negotiated redemption agreements with certain holders of its unsecured senior notes due July 15, 2023 (the "existing notes") and agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021, that will have the overall effect of deleveraging the company's balance sheet.
    • Leslie's, Inc. (NASDAQ:LESL) dropped 33.8% to $6.30 after the company released preliminary results for its fiscal third quarter and announced a CFO transition. The company said it expects fiscal third-quarter revenue to come in at $611 million versus estimates of $703.74 million and seed adjusted earnings in a range of 39 cents to 41 cents per share versus estimates of 69 cents per share. Leslie's also announced that CFO Steve Weddell is stepping down from his role, effective Aug. 7.
    • Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) declined 30.3% to $1.45. Galmed Pharmaceuticals announced pricing of $7 million public offering of 5.6 million shares and warrants at a purchase price of $1.25 per share.
    • TELUS International (Cda) Inc. (NASDAQ:TIXT) fell 28.4% to $10.52 after the company issued FY23 adjusted EPS and revenue guidance below estimates.
    • Fresh Vine Wine, Inc. (NASDAQ:VINE) fell 26.6% to $0.4305 after gaining over 12% on Thursday.
    • Lilium N.V. (NASDAQ:LILM) fell 22% to $1.3200 after the company announced pricing of an upsized $192 million offering.
    • Organigram Holdings Inc. (NASDAQ:OGI) tumbled 21.6% to $1.5215 as the company released its results for the third quarter ended May 31, 2023, revealing net revenue decreased 14% to CA$32.8 million ($25 million), from CA$38.1 million in Q3 fiscal 2022.
    • Funko, Inc. (NASDAQ:FNKO) declined 21.5% to $7.90. Funko said Brian Mariotti will take leave of absence and cease serving as the company’s CEO.
    • Caribou Biosciences, Inc (NASDAQ:CRBU) fell 21.3% to $6.41. Caribou Biosciences announced pricing of its upsized $125 million public offering. The company also reported long-term follow-up data from the dose escalation portion of the ongoing ANTLER Phase 1 trial of CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
    • Opera Limited (NASDAQ:OPRA) fell 21.3% to $21.91 after the company filed for a mixed shelf of up to $300 million.
    • 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares plunged 18.6% to $3.6886.
    • IT Tech Packaging, Inc. (NYSE:ITP) shares dipped 18.3% to $0.4250.
    • Rockwell Medical, Inc. (NASDAQ:RMTI) shares declined 17.5% to $3.39.
    • Frontier Communications Parent, Inc. (NASDAQ:FYBR) shares dipped 16.6% to $13.55.
    • Healthcare Triangle, Inc. (NASDAQ:HCTI) fell 16.3% to $3.60.
    • Inogen, Inc. (NASDAQ:INGN) fell 15% to $8.72. Needham downgraded Inogen from Buy to Hold.
    • Lion Group Holding Ltd. (NASDAQ:LGHL) declined 14.8% to $3.45.
    • Bit Brother Limited (NASDAQ:BTB) fell 14.3% to $0.66 after the company announced pricing of a $50 million registered direct offering.
    • Ault Alliance, Inc. (NYSE:AULT) fell 14.1% to $3.6150 after declining over 20% on Thursday. Ault Alliance recently announced a second partial distribution of TOG Securities of approximately $0.37 for each share of Ault Alliance common stock.
    • CommScope Holding Company, Inc. (NASDAQ:COMM) shares fell 11.8% to $5.76.
    • CareMax, Inc. (NASDAQ:CMAX) fell 11.2% to $2.4250.
    • Beneficient (NASDAQ:BENF) shares fell 10.8% to $2.56.
    • Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) shares dropped 10.5% to $5.14 after the company posted a loss for the second quarter.
    • State Street Corporation (NYSE:STT) fell 10.5% to $69.18 after after the company reported slightly worse-than-expected second-quarter revenues as well as an increase in total expenses.
    • Nokia Oyj (NYSE:NOK) shares fell 10% to $3.9150 after the company reduced net sales guidance and narrowed its operating margin outlook for 2023.
    • Lumen Technologies, Inc. (NYSE:LUMN) shares slipped 9.9% to $1.8550.
    • D-Wave Quantum Inc. (NASDAQ:QBTS) shares declined 9.9% to $2.3697.
    • Hayward Holdings, Inc. (NYSE:HAYW) shares dipped 8.4% to $12.42.
    • Lumentum Holdings Inc. (NASDAQ:LITE) fell 7.7% to $51.32.
    • Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) fell 7% to $0.3265. Aridis recently announced FDA Qualified Infectious Disease Product Designation for AR-301.

     

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $AEHR
    $AIMD
    $AMBO

    CompanyDatePrice TargetRatingAnalyst
    Nokia Corporation Sponsored
    $NOK
    3/13/2026Buy → Neutral
    Arete
    Lumentum Holdings Inc.
    $LITE
    3/12/2026$675.00Hold
    TD Cowen
    Hayward Holdings Inc.
    $HAYW
    3/6/2026$19.00Underperform → Buy
    BofA Securities
    Aehr Test Systems
    $AEHR
    3/2/2026Mkt Perform → Outperform
    William Blair
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    State Street Corporation
    $STT
    2/23/2026$150.00Buy
    Citigroup
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    D-Wave Quantum Inc.
    $QBTS
    2/12/2026Buy
    TD Cowen
    More analyst ratings

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lumentum Thought Leaders to Present at OFC 2026

    Michael Hurlston, CEO and Matt Sysak, CTO to participate in Optica Executive Forum Lumentum Holdings Inc. ("Lumentum") today announced its speaker line-up at the 2026 Optical Fiber Communication Conference and Exposition (OFC) in Los Angeles. Company executives and technical experts will share their perspectives on the optical communication market, including challenges and opportunities, and the technology shaping the future of AI data centers and optical networks. The event will be held from March 15–19 at the Los Angeles Convention Center. Visit Lumentum at booth #1439. Optica Executive Forum Fireside Chat with CTOs: Matt Sysak, 2:00–3:00 p.m. CEO Panel: Michael Hurlston, 3:30–4

    3/13/26 8:00:00 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Ericsson leads the 6G journey toward an intelligent fabric at MWC 2026

    STOCKHOLM, March 13, 2026 /PRNewswire/ -- Ericsson (NASDAQ:ERIC) reinforced its position as the driving force behind the global 6G ecosystem at Mobile World Congress (MWC) Barcelona 2026. As the journey towards 6G continues, the industry is moving from 6G concept to commercial preparation, Ericsson's presence across major 6G announcements during MWC, and in its cutting-edge demos reflects how leading device, silicon and compute partners are working with the company to validate foundational technologies and accelerate ecosystem readiness for AI-native 6G. Ericsson is the engine that drives the 6G ecosystem forward and is engineering the AI-native, globally scalable foundation that the rest of

    3/13/26 3:28:00 AM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Ericsson Annual Report on Form 20-F filed with the SEC

    STOCKHOLM, March 12, 2026 /PRNewswire/ -- On March 12, 2026, Ericsson (NASDAQ:ERIC) filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (SEC). The Annual Report is available on Ericsson's website at https://www.ericsson.com/en/investors. Shareholders may request a hard copy of the Annual Report by contacting the company.NOTES TO EDITORS:FOLLOW US:Subscribe to Ericsson press releases hereSubscribe to Ericsson blog posts herehttps://twitter.com/ericssonhttps://www.facebook.com/ericssonhttps://www.linkedin.com/company/ericssonMORE INFORMATION AT:Ericsson [email protected]  (+46 10 719 69 92)investor.relat

    3/12/26 5:03:00 PM ET
    $ERIC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Porter Brian J. bought $312,475 worth of shares (2,500 units at $124.99), increasing direct ownership by 39% to 8,898 units (SEC Form 4)

    4 - STATE STREET CORP (0000093751) (Issuer)

    3/9/26 4:00:51 PM ET
    $STT
    Major Banks
    Finance

    President & CEO Johnson Kathleen E bought $499,925 worth of shares (78,685 units at $6.35), increasing direct ownership by 0.93% to 8,562,582 units (SEC Form 4)

    4 - Lumen Technologies, Inc. (0000018926) (Issuer)

    2/5/26 5:34:09 PM ET
    $LUMN
    Telecommunications Equipment
    Telecommunications

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nokia downgraded by Arete

    Arete downgraded Nokia from Buy to Neutral

    3/13/26 8:46:03 AM ET
    $NOK
    Radio And Television Broadcasting And Communications Equipment
    Technology

    TD Cowen initiated coverage on Lumentum with a new price target

    TD Cowen initiated coverage of Lumentum with a rating of Hold and set a new price target of $675.00

    3/12/26 8:54:26 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Hayward Holdings upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hayward Holdings from Underperform to Buy and set a new price target of $19.00

    3/6/26 8:18:36 AM ET
    $HAYW
    Industrial Machinery/Components
    Industrials

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Plansky John sold $2,001,552 worth of shares (16,100 units at $124.32), decreasing direct ownership by 22% to 56,162 units (SEC Form 4)

    4 - STATE STREET CORP (0000093751) (Issuer)

    3/12/26 4:05:59 PM ET
    $STT
    Major Banks
    Finance

    SEC Form 3 filed by new insider Ye Qingyan

    3 - SHENGFENG DEVELOPMENT Ltd (0001863218) (Issuer)

    3/11/26 12:16:42 PM ET
    $SFWL
    Trucking Freight/Courier Services
    Industrials

    SEC Form 3 filed by new insider Zheng Guoping

    3 - SHENGFENG DEVELOPMENT Ltd (0001863218) (Issuer)

    3/11/26 12:16:17 PM ET
    $SFWL
    Trucking Freight/Courier Services
    Industrials

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    SEC Filings

    View All

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:17:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:15:16 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Beneficient

    DEF 14A - Beneficient (0001775734) (Filer)

    3/13/26 4:30:42 PM ET
    $BENF
    Finance: Consumer Services
    Finance

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Financials

    Live finance-specific insights

    View All

    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

    ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated ARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026 Cash runway extended into Q2 2028 Investor conference call at 4:30 p.m. ET today Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the fourth quarter and fiscal year 2025, and provided corporate updates. "Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical d

    3/3/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    State Street Investment Management Expands Industry's First Actively Managed Corporate Target Maturity ETFs Suite

    Launch of State Street® MyIncome High Yield Corporate Bond ETFs Enhances Bond Laddering Toolkit for Investors State Street Investment Management announced today the launch of five actively managed target maturity high yield corporate bond ETFs. In providing access to high yield bonds with matching maturity years ranging from 2027 to 2031, the newest State Street MyIncome ETFs help simplify the process of building custom bond ladder portfolios. "In addition to helping manage interest rate risk, bond ladders are an effective strategy for providing income-oriented investors with predictable cash flows and liquidity," said Anna Paglia, Chief Business Officer for State Street Investment Mana

    2/26/26 8:30:00 AM ET
    $STT
    Major Banks
    Finance

    Opera Reports Fourth Quarter and Full-Year 2025 Results Ahead of Expectations, Announces $300 Million Share Repurchase Program

    Fourth quarter revenue increased 22% year-over-year to $177.2 million, exceeding the guidance rangeFourth quarter adjusted EBITDA was $41.9 million, representing a 24% margin, and also exceeding the guidance rangeFor the full year, revenue increased 28% to 614.8 million and adjusted EBITDA was $142.5 million, representing a 23% marginInitiated 2026 guidance, anticipating full-year revenue of $720 - 735 million (17 - 20% growth) and adjusted EBITDA of $167 - 172 million. First quarter 2026 revenue is guided to $169 - 172 million (18 - 21% growth) with adjusted EBITDA of $38 - 40 million, maintaining a strong 23% margin throughout the yearAnnounced major share repurchase program for up to $300

    2/26/26 7:00:00 AM ET
    $OPRA
    Computer Software: Prepackaged Software
    Technology

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Leadership Updates

    Live Leadership Updates

    View All

    Beneficient Appoints Mack H. Hicks to Board of Directors

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced the appointment of Mack H. Hicks as a member of the Company's Board of Directors (the "Board"). Mr. Hicks currently serves as Chief Executive Officer of Hicks Holdings LLC, the Dallas-based family office with operating private equity and real estate investment businesses founded by his late father and private equity pioneer, Thomas O. Hicks, who served as Chairman of the Board of Beneficient until his passing in December of 2025. Mr. Hicks also

    3/12/26 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    Lumentum to Join the S&P 500 Index

    Lumentum Holdings Inc. ("Lumentum"), a global leader in optical and photonic solutions, today announced that it has been selected to join the prestigious S&P 500 index. According to S&P Dow Jones Indices, Lumentum will be added to the benchmark index before the market opens on Monday, March 23, 2026. This transition marks a significant milestone for the company as it moves from the S&P MidCap 400 to the S&P 500, reflecting its substantial growth and corresponding increase in market capitalization. "Inclusion in the S&P 500 is a monumental achievement for our company and a credit to our global workforce," said Michael Hurlston, President and CEO. "It reflects our vital role in helping cust

    3/10/26 8:00:00 AM ET
    $LITE
    Telecommunications Equipment
    Telecommunications

    Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

    Special Meeting to Approve Acquisition of Sanity Group GmbH Organigram Global Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the "Circular") and related materials (the "Meeting Materials") for its annual and special meeting (the "Meeting") of the holders of its common shares (the "Shareholders") to be held on March 30, 2026. The Circular is available under Organigram's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. In addition to routine annual business to be conducted, Shareholders at the Meeting will be asked to consider and vote u

    3/10/26 6:00:00 AM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $AEHR
    $AIMD
    $AMBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Frontier Communications Parent Inc.

    SC 13D/A - Frontier Communications Parent, Inc. (0000020520) (Subject)

    12/12/24 4:15:11 PM ET
    $FYBR
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SC 13D/A filed by Organigram Holdings Inc.

    SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

    12/10/24 7:10:15 PM ET
    $OGI
    Biotechnology: Pharmaceutical Preparations
    Health Care